Table 2.
Treatment characteristics of patients initiating 1L treatment
| Treatment characteristic | Overall (n = 94) | Avelumab (n = 28) | Non‐avelumab IO (n = 26) | Chemotherapya (n = 40) |
|---|---|---|---|---|
| Time from laMCC/mMCC diagnosis to 1L treatment initiation, median (range), weeks | 7.7 (0.0–165.4) | 6.0 (0.1–161.7) | 15.3 (0.0–165.4) | 5.9 (0.3–164.0) |
| Patients with surgical resections prior to 1L treatment, n (%) | 20 (21.3) | 6 (21.4) | 4 (15.4) | 10 (25.0) |
| Patients with radiation treatments prior to 1L treatment, n (%) | 11 (11.7) | 2 (7.1) | 5 (19.2) | 4 (10.0) |
| Patients with 1L concurrentb surgical resections, n (%) | 7 (7.4) | 3 (10.7) | 1 (3.8) | 3(7.5) |
| Patients with 1L concurrentb radiation treatments, n (%) | 23 (24.5) | 6 (21.4) | 6 (23.1) | 11 (27.5) |
| Patients who discontinued treatment, n (%)c | 78 (83.0) | 18 (64.3) | 21(80.8) | 39 (97.5) |
| Reasons for treatment discontinuation, n (%)d | ||||
| Disease progression | 20 (25.6) | 6 (33.3) | 6 (28.6) | 8 (20.5) |
| Toxicity | 14 (17.9) | 2 (11.1) | 7 (33.3) | 5 (12.8) |
| Death | 11 (14.1) | 3 (16.7) | 4 (19.0) | 5 (12.8) |
| Physician preference | 9 (11.5) | 5 (27.8) | 1 (4.8) | 2 (5.1) |
| Patient choice | 2 (2.6) | 0 | 1 (4.8) | 1 (2.6) |
| Decline in performance status | 1 (1.3) | 0 | 1 (4.8) | 0 |
| Completed treatmente | 20 (25.6) | 1 (5.6) | 1 (4.8) | 18 (46.2) |
| Not documented | 3 (3.8) | 2 (11.1) | 1 (4.8) | 1 (2.6) |
| TTD, median (95% CI), months | 3.8 (3.0–5.6) | 10.5 (5.3–14.3) | 7.3 (2.5–18.2) | 2.2 (1.9–3.5) |
a
Most common 1L treatments among chemotherapy patients were carboplatin + etoposide (n = 22) and cisplatin + etoposide (n = 10).
b
Concurrent treatment occurs during 1L therapy (between start and end dates).
c
Discontinuation before the end of the follow‐up period.
d
Patients could have multiple reasons for treatment discontinuation.
e
Physician notes were used to find out if the patient completed treatment.
Abbreviations: 1L, first‐line; CI, confidence interval; IO, immunotherapy; laMCC, locally advanced MCC; mMCC, metastatic Merkel cell carcinoma; TTD, time to discontinuation.